id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-340232-cadu5ah8	Aliter, Kholoud F.	Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19	2020-09-01		.txt	text/plain	5317	323	34	Considering the pathogenesis of COVID-19 pandemic, thrombin inhibitors may exert multiple potential therapeutic benefits including antithrombotic, anti-inflammatory, and antiviral activities. In this review, we put forward thrombin, a trypsin-like serine protease belonging to the coagulation process, as a potential drug target to develop adjunct therapeutics for COVID-19, particularly for the critically ill patients. In this model, inhibition of thrombin activity by a specific inhibitor reported as NAPAP (mostly likely is dabigatran) immediately led to a reduction in the expression of inflammatory markers of TNF-α, C-X-C motif chemokine ligand-9 (CXL9), and C-C motif chemokine ligand-1 (CCL1) and in the expression of the coagulation markers of factor X and PAR-1 in the brain [53] . Together, considering thrombin's roles in thrombosis, inflammation, and viral infections (Fig. 1) , it is plausible to expect that inhibiting thrombin activity may eventually promote not only anticoagulant effect, but also anti-inflammatory and antiviral effects.	./cache/cord-340232-cadu5ah8.txt	./txt/cord-340232-cadu5ah8.txt